John Halliday

TL;DR: A first-in-human trial of a prime-boost vaccine strategy for HCV, with durable, broad, sustained, and balanced T cell responses, characteristic of those associated with viral control, paving the way for the first efficacy studies of a prophylactic HCV vaccine.

TL;DR: Improvement in SAP to below 1.5 ULN is associated with better outcome and reduced risk of CCA in PSC and was comparable to the achievement of complete normalization of SAP.

TL;DR: A comparative analysis of infected people with distinct clinical outcomes has enabled the characterization of many important innate and adaptive immune processes associated with viral control, and it is clear that a successful HCV vaccine will need to exploit and enhance these natural immune defense mechanisms.

TL;DR: Compared to patients with isolated CD, patients with PSC/CD were less likely to smoke or have ileal disease, and less commonly progressed to cancer, liver transplantation, or death.

TL;DR: Vaccination with potent HCV adenoviral vectored vaccines fails to restore T‐ cell immunity except where there is genetic mismatch between vaccine immunogen and endogenous virus; this highlights the major challenge of overcoming T‐cell exhaustion in the context of persistent antigen exposure with implications for cancer and other persistent infections.